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     Abstract 
Background: The evidence base for the effectiveness of cognitive behaviour therapy 
(CBT) for treating Body Dysmorphic Disorder (BDD) is weak. Aims: To determine if 
CBT is more effective than anxiety management (AM) in an out-patient setting. 
Method: A single blind, stratified parallel-group randomized controlled trial. The 
primary endpoint was at 12 weeks, and the Yale Brown Obsessive Compulsive Scale 
for BDD (BDD-YBOCS) was the primary outcome measure. Secondary measures for 
BDD included the Brown Assessment of Beliefs (BABS), the Appearance Anxiety 
Inventory (AAI) and the Body Image Quality of Life Inventory (BIQLI). The outcome 
measures were collected at baseline and week 12. The CBT group, unlike the AM 
group, had 4 further weekly sessions that were analysed for their added value. Both 
groups then completed measures at their 1-month follow-up.  Forty-six participants, 
with DSM-IV diagnosis of BDD including those with a delusional BDD were 
randomly allocated to either CBT or AM. Results: At 12 weeks, CBT was found to be 
significantly superior to AM on the BDD-YBOCS (β = -7.19, S.E. (β) = 2.61, p < .01, 
C.I. = -12.31, -2.07, d  0.99) as well as the secondary outcome measures of the BABS, 
AAI and BIQL. Further benefits occurred by Week 16 within the CBT group. There 
were no differences in outcome for those with delusional BDD or depression. 
Conclusions: CBT is an effective intervention for people with BDD even with 
delusional beliefs or depression and is more effective than anxiety management over 
12 weeks.  
 
Keywords Body Dysmorphic Disorder, Cognitive Behaviour Therapy, Anxiety 
Management, randomised controlled trial 
Declarations of Interest: None  
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Introduction 
Body Dysmorphic Disorder (BDD) is characterised by a preoccupation with a 
perceived defect(s) or flaw(s) in physical appearance that is either not noticeable or 
appears only slight to others. In addition, the preoccupation must be significantly 
distressing or cause impairment in social, occupational or other important areas of 
functioning. DSM5 has adder a further criterion to the diagnosis of BDD that is at 
some time point during the course of the disorder, the individual has performed 
repetitive behaviours (e.g. mirror checking) or mental acts (e.g. comparing) [1, 2]. 
BDD is more common than previously recognized with a prevalence of about 2% in 
the general population [3, 4]. It is a chronic disorder, which persists for many years if 
left untreated [5]. There is a high rate of psychiatric hospitalisation, suicidal ideation 
and completed suicide [6, 7]. It is poorly identified in psychiatric populations where, 
patients often do not reveal their problem, because of shame and stigma, or present 
with symptoms of depression, social anxiety or obsessive-compulsive disorder (OCD) 
when their main problem is BDD [5, 8]. In addition, many resources are wasted on 
those who attend dermatological and cosmetic surgery settings [9-11]. 
For pharmacotherapy of BDD, there are three randomised controlled trials 
(RCT) [12-14]. Phillips et al. [12] found that a selective serotonergic reuptake 
inhibitor (SSRI),  fluoxetine was more effective than a placebo, and that delusional 
BDD made no difference to outcome. Phillips [14] also showed that adding an anti-
psychotic, pimozide, to a SSRI was no more effective than adding a placebo in those 
who had not responded to a SSRI alone. Anti-psychotics are not therefore 
recommended in the NICE guidelines for the treatment of BDD [15, 16]. SSRIs are 
recommended for moderate to severe BDD with the proviso that, a high rate of relapse 
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is likely to occur on discontinuation of the SSRI [17]. However data on relapse rates 
with discontinuation of SRIs are very minimal, based on just one chart-review study.  
There has been three small pilot RCTs of Cognitive Behaviour Therapy (CBT) 
in adults with BDD that have demonstrated greater effectiveness of CBT compared to 
a wait-list [18-20]. However, the participants in Rosen et al’s [19] study were not that 
representative as the sample contained only women, several of whom who had 
disordered eating, and they were less impaired than those seen in psychiatric settings. 
Furthermore, the therapy was delivered in a group format. None of the previous RCTs 
determined whether the CBT was effective for delusional BDD or comorbid 
depression. Lastly none of the studies contained a comparison treatment to control for 
attention and non-specific therapeutic factors. Since these pilot trials, knowledge of 
phenomenology of BDD has increased and we have further developed a cognitive 
behavioural model to guide treatment [21, 22]. The aim of this research was therefore 
to determine if our CBT that is specific for BDD is more effective than a credible 
non-specific alternative (anxiety management) over 12 weeks for treating BDD with 
or without delusional BDD in adults aged 18 and over. Anxiety Management (AM) 
(based on applied relaxation) was chosen to control for therapist attention and alliance 
as well as homework. AM is not however a “placebo” – it is an active treatment that is 
effective for generalised anxiety disorder [23]. It has fared less well in previous 
studies against CBT for OCD [24] or health anxiety . However AM did as well as 
CBT in OCD with Asperger’s Syndrome [25], and in multiple somatoform symptoms 
[26]  and in the long term in one study for obsessions without prominent compulsions 
[27].  
Objectives 
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 In the current study we tested the hypotheses that CBT would be superior to 
AM in reducing symptoms of BDD at a primary outcome point of 12 weeks. In 
addition, an improved outcome within the CBT group after an extra 4 sessions of 
therapy was tested. Further secondary aims of this study were to explore (a) whether 
CBT was as effective in those with delusional BDD and depression, (b) whether the 
gains in CBT and AM were maintained at 1-month follow-up.   
Method  
Design 
This was a single-blind stratified (by presence of delusional BDD and severity 
of depression), parallel-group randomised controlled trial conducted in the UK. The 
allocation ratio used was 1:1. There were no changes to the trial design after 
commencement.  
Participants 
Inclusion Criteria   
The eligibility criteria for participants were as follows:   
(1) Have a diagnosis of BDD according to DSM-IV diagnostic criterion [1] as their 
main problem.  DSM-IV was used as this was operational at the time the study began. 
BDD was defined as their main problem if it was their reason for referral to treatment, 
their symptoms were not explained better by any other mental disorder, and their 
clinical outcome measures were indicative of BDD being their most severe mental 
concern. A trained clinician made the diagnosis on the Structured Clinical Interview 
for DSM-IV Axis I Disorders [28]. When there was comorbidity, there had to be 
agreement between the clinician and the patient that their appearance was their main 
concern. Participants with an additional diagnosis of delusional BDD were included 
when the diagnosis referred to delusional beliefs about being ugly or defective. 
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(DSM-IV allows double coding of both BDD and delusional BDD, which does not 
occur in DSM-5). Other types of somatic delusions and non-appearance related 
delusions were excluded.    
(2) Have a total of 24 or more on the Yale Brown Obsessive Compulsive Scale 
modified for BDD (BDD-YBOCS) [29]. This was the equivalent of scoring at least 2 
(“moderate”) on all 12 items.  
(3) Be aged 18 or above. 
(4) Be willing to travel to the treatment centre for weekly sessions.  
(5) Either not be on psychotropic medication or, if taking medication, be on a dose 
that had been kept stable for at least 12 weeks prior to randomization with no plans to 
increase the dose during the course of the study. This was subsequently monitored 
during the study. 
Exclusion criteria 
Participants were excluded if they:  
(1) Had a current or lifetime diagnosis of schizophrenia, schizoaffective or bipolar 
affective disorder.  
(2) Had severe self-neglect or suicidal intent that required hospitalisation. 
(3) Had a current diagnosis of alcohol/substance dependence, anorexia nervosa or 
borderline personality disorder that required treatment first.  
(4) Had body image concerns that primarily related to weight and/or shape or fulfilled 
criteria for “Eating Disorder Not Otherwise Specified”.   
(5) Were currently receiving any other form of psychotherapy.  
(6) Had received CBT for BDD in the past 6 months, which was judged by the 
clinician as competently delivered.  
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(7) Did not have sufficient command of English to participate in the therapy and 
complete rating scales. 
The recruitment took place between April 2009 and March 2012 at a single 
centre, which was an outpatient clinic at the Centre for Anxiety Disorders and Trauma 
at the Maudsley Hospital, London. The centre is part of an Improving Access to 
Psychological Therapies (IAPT) or “primary care” service. It also takes national 
referrals (or “secondary care” service where patients are also under the care of their 
own local community mental health team). It is also part of a national funded Highly 
Specialised service for severe treatment refractory OCD and BDD (which is a 
“tertiary care” service).  
Interventions  
The two interventions to be evaluated were: 
(1) Cognitive behaviour therapy (CBT). This is a focussed form of 
psychotherapy that consisted of 12 weeks of individual sessions of 1 hour at weekly 
intervals. It followed a treatment manual [30]. The first stage consisted of engagement 
in a developmental understanding of the problem and setting up an alternative view of 
the problem to be tested in therapy. Imagery re-scripting followed for past aversive 
memories that were associated with the onset (for example bullying) [31].  A 
formulation further identified factors that were maintaining the person's preoccupation 
and distress relating to perceived ugliness. These included understanding the 
unintended consequences of their safety-seeking behaviours that maintain 
preoccupation and distress in the long term.  The behaviours were aimed at either: (i) 
threat detection and monitoring (for example, cognitive processes such as self-
focussed attention or behaviours such as mirror checking) or (ii) preventing feared 
consequences by avoidance (for example, comparing or camouflaging a perceived 
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defect) or (iii) attempts to undo the appearance concerns (for example, seeking a 
cosmetic procedure). The therapist aimed to help individuals to identify their beliefs 
about processes such as ruminating or mirror gazing [32]; to conduct behavioural 
experiments that tested out their expectations or an alternative understanding of the 
problem; and to gradually drop the safety seeking behaviours and test out their fears 
in situations or activities that are avoided. These are done in vivo within and between 
sessions for homework. It does not focus on evaluations such as being ugly. Self-
monitoring and habit reversal was used for any skin-picking.  
(2) Anxiety Management. The treatment followed a standard protocol [33] . It was 
provided once a week for 12 weeks, with each session lasting one hour. AM was 
planned to have a similar therapeutic alliance, support, and homework to the CBT 
group.  The rationale provided was that when triggered, the person would experience 
threat and negative thoughts about their appearance. This in turn would lead to 
physical symptoms of anxiety and magnify the perceived threat. The treatment 
consisted of (1) practising progressive muscle relaxation and breathing daily; and (2) 
identifying triggers and physical symptoms associated with appearance-related 
anxiety, and utilising brief muscle relaxation and breathing techniques in trigger 
situations. 
The aim was to reduce baseline anxiety, anxiety in trigger situations or when 
they became anxious about their appearance. AM was not given for 16 weeks, in 
contrast to CBT, as the researchers did not consider it feasible to continue treatment 
for such a length of time.  
After AM, there was a wait-list for 4 weeks when participants were able to 
cross-over into CBT, if they still fulfilled criteria for BDD. At the very beginning of 
treatment, both groups were told that after the end of their treatment they would be 
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offered another type of treatment, to balance the obligation to provide care. Twelve 
weeks of hourly sessions were implemented for both treatments, as it was considered 
unethical to deny participants receiving Anxiety Management, the more established 
treatment of CBT, for a period longer than 12 weeks. Twelve weeks was considered 
the maximum time limit for gains from AM and sufficient to determine whether CBT 
was superior to AM. The primary endpoint was therefore taken at 12 weeks. Further 
research is required to determine the optimum length of CBT for BDD that may be 
considered longer than 12 weeks. For both CBT and AM there was no direct targeting 
of other symptoms such as depression or other comorbidity.  
Evaluation of therapy   
 Participants completed the Credibility and Expectancy Questionnaire at 
baseline [34]. The questionnaire measures the credibility and treatment expectancy of 
the treatment assigned. Each sub-scale has a range of 3 to 27. A higher score indicates 
higher credibility or expectation for improvement. 
Three therapists with at least 5 years of experience and either a Doctorate in 
Clinical Psychology or accreditation by the British Association for Behavioural and 
Cognitive Psychotherapies delivered the interventions. All three therapists were 
crossed to deliver both treatments. This was determined by clinician expertise and 
availability. They were trained and supervised weekly in the delivery of the 
treatments. Therapy sessions were audio-recorded (when consented to in writing) and 
a random sample of 1 in 10 audiotapes was rated blind by three accredited CBT 
therapists using an adherence rating scale developed for the study in order to measure 
treatment fidelity and quality. Elements of therapy, such as “use of behavioural 
experiments” (CBT), “teaching breathing techniques” (AM), and other non-specific 
components of both treatments such as “agenda setting” were rated as to whether they 
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were included in treatment sessions. Scores for included components of therapy were 
summed to give a total. In addition, therapist directiveness was rated on a 5-point 
Likert scale ranging from 0 (very non-directive) to 4 (very directive), and therapeutic 
relationship was rated on a 4-point Likert scale from 0 (poor) to 3 (very good). 
Independent t-tests were conducted on therapy components, therapist directiveness 
and therapeutic relationship mean scores. 
Outcomes  
Information was collected on age, sex, ethnicity, marital status, occupation, 
and comorbid diagnoses using the Structured Clinical Interview for DSM-IV Axis I 
Disorders. For all participants taking a SSRI, a fluoxetine equivalent dose was 
calculated (for example fluoxetine 20mg was equivalent to citalopram 20mg or 
sertraline 50mg).  
All outcome measures apart from the Credibility Expectancy Questionnaire 
(CEQ) were repeated at baseline, and week 12 (primary end-point) in both groups. 
The CBT group also completed measures at 16 weeks, after receiving 4 extra 
treatment sessions. Measures were repeated at 1-month follow-up in both groups. The 
CEQ was administered once at pre-treatment. 
The primary outcome measure was the Yale Brown Obsessive Compulsive 
Scale modified for BDD (BDD-YBOCS) [29]. This is a clinician rated scale 
administered by a trained blind assessor. The range is 0-48. Cronbach’s alpha for the 
scale is .80. Response to treatment is defined as 30% or greater decrease in the total 
BDD-YBOCS, which best corresponded to “much improved” on the Clinical Global 
Impression (CGI) scale. In the original validation study, this cut off score produced 1 
false negative (96% sensitivity), that is 1 who was rated as much or very much 
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improved on the CGI was not classified as a responder on the BDD-YBOCS using the 
30% threshold [29].  
The following were secondary outcome measures:  
(1) Brown Assessment of Beliefs Scale (BABS) [35]  
The BABS is a 7-item clinician scale rated by a blind assessor to measure the strength 
of conviction in a belief (e.g. “I am as ugly as the Elephant man”). Each item is rated 
from 0 (non-delusional belief, or least pathological) to 4 (delusional belief, or most 
pathological) and total scores range from 0-24. Higher scores represent increasing 
delusionality of beliefs. Respondents are classified as having delusional BDD beliefs 
if the total score is 18 or more, and if they score 4 on the first item indicating they are 
completely convinced that their belief is accurate.  
(2) Montgomery Asberg Depression Rating Scale (MADRS) [36] 
The MADRS is a 10-item clinician scale rated by a blind assessor to measure 
symptoms of depression. Each item is rated on a 7-point Likert scale from 0 indicating 
normal or no difficulties, to 6 and the range is 0 to 60. Higher scores reflect greater 
symptomatology. A MADRS total score ≥ 25 is regarded as moderate and  > 31 as 
severe symptom [37].  
The following self-report measures were administered weekly:  
(1) Appearance Anxiety Inventory (AAI) [38] 
The AAI is a 10-item self-report questionnaire for measuring frequency of avoidance 
behaviour and threat-monitoring (e.g. checking; self-focussed attention) that are 
characteristic of a response to a distorted body image. Each item is scored from 0 
(“not at all”) to 4 (“all the time”), and the range of total scores is from 0 to 40 with 
higher scores reflecting greater frequency of the responses. The AAI has a Cronbach’s 
alpha of .86.  
12 
 
 2) PHQ-9 Depression Severity [39]  
The Patient Health Questionnaire (PHQ) is a 9-item self-report measure of depression. 
Each item is scored from 0 (“not at all”) to 3 (“nearly every day”), and the summed 
total score ranges from 0 to 27 with higher scores reflecting greater symptomatology 
of depression. Cronbach’s alpha for the scale is .89.  
3) Generalized Anxiety Disorder (GAD-7)[40]  
The GAD-7 is a 7-item self-report measure for symptoms of generalized anxiety. 
Each item is scored from 0 to 3 and a summed total score ranges from 0 to 21, with 
higher scores reflecting greater symptomatology. Cronbach’s alpha for the measure is 
.92.   
4) Body Image Quality of Life Inventory (BIQLI) [41, 42].  
The BIQLI is a 19-item self-report scale that measures the impact of body 
image concerns on a broad range of life domains (e.g. sense of self, social 
functioning, sexuality, emotional well-being, exercise, grooming). The BIQLI is 
scored as an average numeric score of all the items from -3 (“very negative effect”) to 
+ 3 (“very positive effect”). Cronbach’s alpha of the scale is .95. 
Sample size  
A sample size of 20 per group was calculated to give 90% power and a two-
sided 5% significance for detecting a beneficial difference of 8 and standard deviation 
of 7 on the BDD-YBOCS between CBT and anxiety management. These assumptions 
were made based on a previous RCT of CBT in BDD [18]  and approximates to a 
reduction of 30% on the BDD-YBOCS and clinically significant improvement in 
BDD symptoms [29]. There was an anticipated 10% drop-out giving a planned sample 
size of 22 per group or 44 in total. There were no planned interim analyses or stopping 
rules.  
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Randomization 
Sequence generation  
Randomization was conducted via the UKCRC-registered King’s Clinical 
Trials Unit using a web-based system. Randomization was at the level of the 
individual participant, by the method of minimization stratified by (1) the presence or 
absence of delusional beliefs on the BABS and (2) either high score (25 or above on 
the MADRS) or a low score (below 25) [37]. The first 4 patients were randomized 
using simple randomization to create an initial level of imbalance. The minimization 
algorithm contained a 20% random component for subsequent patients, to maintain 
pre-randomization allocation concealment. Patients were told they were being 
randomized to two different types of psychological therapy and if they wished could 
switch to the alternative therapy after 12 weeks.  
Allocation concealment mechanism 
The allocation sequence was concealed from the research assessor. An email 
confirming the treatment allocation was sent directly to the therapist.  
Implementation  
The research assessor enrolled participants in the trial and gained written 
informed consent for their participation in the trial as well as treatment. 
Blinding  
The research assessor administering the observer rated scales was blinded to 
group assignment at baseline and 12 weeks. She had no access to clinician notes, 
which were kept in a different office and was not involved in supervision or 
discussion of treatment. While the blind assessor was located in the same building as 
the therapists, they worked on separate floors. As all therapists were crossed, should 
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the assessor have been at risk of seeing a patient entering a therapist’s office, blinding 
would not have been broken. 
Statistical methods  
All data were entered into Statistical Package for the Social Sciences (SPSS), 
version 21 for Windows. The analysis of effectiveness was based on “intention to 
treat”, utilising data from those participants who provided baseline and follow-up 
data, regardless of whether they completed treatment. To reduce missing data from 
partially filled in questionnaires, the average score was computed for questionnaires 
where only one item was missing. In order to correct for multiple missing item data 
for questionnaires with two or more missing items, and in some cases entire missing 
measures, multiple imputation was used. Group, baseline BDD-YBOCS, MADRS, 
BABS and AAI scores were entered into the model as predictors of missing data and 
30 imputations were run. In order to assess baseline equivalence of the groups, 
proportions of categorical variables at baseline (for example demographics) were 
compared between groups using Fisher’s exact tests. Values of continuous measures 
at baseline were compared using the Mann-Whitney U-test. Primary and secondary 
effectiveness analysis for both groups was based at 12 weeks. Results are summarised 
by mean differences and corresponding 95% confidence intervals. All measures were 
two-tailed. 
Linear mixed models were conducted to determine the predictive value of 
treatment group, and or time on outcome variable scores. These measures had a 
significance of 5% (two-sided).  Repeated-measures t-tests were then used to 
determine where significant differences occurred. Where more than one t-test has 
been conducted on each variable, a Bonferroni correction was used to decrease the 
risk of type I error. For the CBT group, repeated-measures t-tests had a significance 
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level of 1.66%, and the AM group had a repeated-measures t-test significance level of 
2.5% 
A logistic regression analysis was used on binary outcomes as either “much 
improved” ( ≥ 30% change on BDD-YBOCS) or not recovered. A 30% or more 
decrease in BDD-YBOCS score was considered “much improved” on the basis that it 
is significantly correlated with response of BDD symptoms measured using the 
Clinical Global Impressions scale (CGI) [29, 43]. We conducted a stepwise multiple 
regression analysis to determine whether delusional beliefs on the BABS or severely 
depressed mood on the MADRS ( > 31) predict response.  
Ethics 
  The study had ethical approval from the Institute of Psychiatry and South 
London and Maudsley NHS Trust Ethics Committee. (NHS REC ref no: 09/H0907/9). 
Neither the original study design, nor the original treatment length was changed 
during the study.   
     Results  
Figure 1 is a CONSORT trial flowchart of the numbers assessed, allocated to 
each group, receiving intended treatment, completing the study protocol and being 
analysed for the primary outcome.  
--------------------------------FIGURE 1 ABOUT HERE --------------------------------- 
The recruitment took place between April 2009 and March 2012. Follow-ups 
took place between December 2009 and September 2012. Participants attended 
therapy sessions once a week. The trial ended when all participants had completed 
follow-up. 
Treatments were acceptable to both groups with no significant difference in 
the number of drop-outs between the groups (Chi square with Yates correction 0.33, p 
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= .56). Table 1 provides baseline demographic and clinical characteristics for all 
participants and for each group. As a group they would be regarded as in the moderate 
to severe range of BDD. Over half were diagnosed as having a delusional BDD, 
nearly two-thirds having had a trial of at least one SSRI in the past and one third 
having had at least one cosmetic procedure in the past. A slightly lower range of 
general comorbidity is demonstrated in this sample in comparison to previous surveys 
(see Table 1). 
--------------------------------TABLE 1 ABOUT HERE -------------------------------- 
The CBT group had 21 participants and the AM group had 25. There were no 
significant differences between the two groups in the demographics and other baseline 
variables. Of note is that both groups rated the credibility of the treatment as equally 
low and had a poor expectancy of change. Eighty-three percent desired at least one 
cosmetic or dermatological procedure. Nearly half the participants were stabilised on 
a selective serotonin reuptake inhibitor (SSRI) (either fluoxetine, citalopram, or 
sertraline). There was no significant difference between treatment groups in the 
frequency of participants taking an SSRI or the dose prescribed.  Apart from the 
SSRIs, one participant in the CBT group was taking zopiclone 3.75mg at night, one 
participant in the AM group was taking a Selective Noradrenergic and Serotonergic 
reuptake inhibitor (SNRI) (venlafaxine) 150mg daily, one was taking St John's Wort 
900mg daily and one was taking quetiapine 50mg daily. There were no changes in 
medication type or dosage prescription throughout the duration of the study.  
The main features of preoccupation in the whole group, in order of prevalence 
were; skin (n = 8, 17.4%), face in general (n = 7, 15.2%), nose (n = 7, 15.2%), legs (n 
= 3, 6.5%) body hair (n = 3, 6.5%), and all other concerns (n = 18, 39.2%).  
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Blind ratings of session recordings for the CBT group indicated that there was 
a mean of 15.3 (SD = 4.7) components of CBT per session and zero components of 
AM per session t (46) = 15.75, p < .001. For the AM group there was a mean of 15.60 
(SD = 6.60) components of AM per session and mean of 0.21 (SD = 0.50) 
components of CBT per session t (46) = 11.57, p < .001. There were therefore no 
violations of CBT being used in AM and vice versa.  In terms of blind ratings of the 
therapeutic relationship, CBT (Mean = 2.42, SD = 0.83) did not differ to AM (Mean = 
2.17, SD = 0.64) t (46) = 1.17, p = .25.  Equally, for therapist directiveness, CBT 
(Mean = 2.25, SD = 0.68) did not differ to AM (Mean = 2.38, SD = 0.97) t (46) = -.51, 
p = .61.    
Table 2 shows the linear change in dependent variable scores from baseline to 
week 12 and interaction between group and time for all outcome measures.    
---------------------------------TABLE 2 ABOUT HERE ---------------------------- 
There was a significant group by time interaction for the primary outcome 
(BDD-YBOCS) and other body image measures (BABS, AAI, and BIQLI scores) at 
week 12. There was no group by time interaction for depression (MADRS or PHQ-9) 
or general anxiety (GAD-7). A main effect of time predicted BDD-YBOCS and AAI 
scores across both time points. Treatment group predicted BIQLI scores. Table 3 
provides mean, standard deviation and effect size, for each group, across 
measurement points, and the Cohen’s d effect size between CBT and AM for all 
outcome measures. Large effect sizes of 1 between CBT and AM at 12 weeks were 
found for BDD-YBOCS and AAI scores. 
    -------------------------------TABLE 3 ABOUT HERE --------------------------------- 
For within-group analysis of CBT there was a significant decrease across all 
the measures (including depression and general anxiety) at week 12. For the AM 
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group there was a significant decrease only for the BDD-YBOCS and AAI at week 
12.  
The number of responders (defined as a decrease of 30% or more on the BDD-
YBOCS) at 12 weeks was 10/21 (48%) in the CBT group and 3/25 (12%) in the AM 
group χ2 (1) = 6.20 p = .013.  For the CBT group, after 16 sessions, 11/21 (52%) were 
responders, McNemar’s Test n = 21, Exact p = .25. At one-month follow-up for the 
CBT group, all 11 responders (100%) had maintained their 30% BDD-YBOCS score 
decrease (McNemar’s Test n = 21, Exact p = 1.00).  At 1 month follow-up for the AM 
group all 3 responders (100%) had also maintained recovery, McNemar’s Test n = 25, 
Exact p = 1.00. CBT was also superior to AM in gradually reducing the cognitive 
processes and behaviours that are thought to maintain BDD on the AAI (see Figure 2, 
supplementary material).  
Pre-specified subgroups of those with comorbid depression or delusional BDD 
at baseline were compared over time. Table 4 (in supplementary material) shows the 
linear change in blind assessor scores from baseline to week 12 for the subgroups 
(depressed vs non-depressed and delusional BDD vs non-delusional BDD) within 
both treatment groups.  
The interaction between time and comorbidity at baseline was not significant 
across both treatment groups for the BDD-YBOCS. This indicates that the treatment 
was just as effective over time for both subgroups. Delusional BDD significantly 
predicted BDD-YBOCS scores in the CBT group. Table 5 (in supplementary 
material) shows outcomes with estimated effect sizes for subgroup comparisons at 
baseline and week 12 and baseline to week 16 for CBT. Both Table 4 and Table 5, 
display findings with decreased power due to their representation of a smaller 
subgroup.  
19 
 
Those who with delusional BDD at baseline in the CBT group had 
significantly higher baseline scores on the BDD-YBOCS than those who did not have 
delusional BDD. This difference was no longer significant by the end of treatment, 
indicating that CBT was associated with a large decrease in BDD-YBOCS scores for 
participants with delusional BDD.   
Finally, there was no difference between the groups in terms of treating severe 
depression. Five out of 9 (56%) participants in the CBT group who were severely 
depressed at baseline, and 4/11 (36%) who were severely depressed at baseline from 
the AM group had recovered from depression at week 12, (χ2  (1)= 1,73. p =.19). 
Those 5 from the CBT group, remained recovered at week 16 after their final 
treatment session McNemar’s Test n = 21, Exact p = 1.00. At one month follow-up 
conducted for the CBT group, 5 participants remained recovered, indicating that the 
effect of treatment on depression was maintained, McNemar’s Test n = 9, Exact p = 
1.00. Equally, for the AM group, 4 participants indicated recovery from severe 
depression that at one month follow-up, McNemar’s Test n = 21, Exact p = .1.00  
Multiple regression analysis was conducted to find predictors of BDD-
YBOCS outcomes. Duration of BDD, depression, and strengths of beliefs (on the 
BABS) at baseline were not significant predictors of BDD-YBOCS outcomes. There 
were no harms or unintended effects to participants in either group.  
Discussion 
This is the first study to examine the efficacy of CBT as compared to another 
credible psychological treatment for BDD. The study demonstrated that CBT that is 
targeted at BDD is more effective than AM after 12 weeks when evaluated using 
specific measures for BDD for the group by time interaction. AM also had a 
significant effect on reducing BDD-YBOCS, AAI and depression over time at week 
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12 but CBT had a larger effect size than AM that was significant across all the 
measures. CBT was just as effective in those with delusional BDD or in those who 
were significantly depressed. Therefore CBT should not be regarded as only suitable 
for those with good insight or who are not depressed.  Overall, the results of the 
current study support previous studies [18-20] regarding the effectiveness of CBT for 
BDD, but also advances the field, as the current study included an active 
psychological treatment (AM) that was compared against CBT, while previous studies 
only used wait-list control and have not examined effectiveness in comorbid 
delusional BDD or depression.  
It may be a concern that the AM group did not show within-group 
improvements in GAD-7 scores, whereas the CBT group did. However AM was not 
targeting generalised anxiety and worry symptoms, it was specifically aimed at 
anxiety related to appearance, to be applied for use in situations when patients felt 
particularly anxious about their appearance.  
The strengths of the study are that the groups were matched prior to 
randomization and the comparator controlled for the passage of time and therapist 
attention. The treatments were rated as equally credible, the therapists were rated as 
having an equally good therapeutic alliance and both groups had homework tasks for 
practice. The cohort in the current study was more severe (in terms of severity on the 
BDD-YBOCS, the proportion who had had a previous treatment with a SSRI and the 
proportion who desired a cosmetic procedure) than those recruited for previous RCTs 
in CBT v a wait-list [18-20]. Current comorbidity was however slightly low for this 
population compared to other studies.   
There are two previous RCTs of CBT v a wait-list that used the BDD-YBOCS 
as the main outcome measure. The within-group effect size in this study at 16 weeks 
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was 1.67, which is similar to that of Veale et al.[18] (1.57) and Rabiei et al.,[20] 
(1.49). The frequency of responders in the CBT group on the BDD-YBOCS (52%) is 
similar to the trial of fluoxetine -v- a placebo in BDD [12]. The fluoxetine trial 
however had a lower within-group effect size on the BDD-YBOCS of 1.36. Open 
label case series of SSRIs have however found response rates of between 63-73%  
[44]. However one should be cautious about comparing effect sizes in previous RCTs 
of BDD as the numbers in all the trials are small and participants may have been less 
severe in some of the studies compared to this trial. However the findings strengthen 
the UK NICE guidelines on BDD in recommending CBT for BDD including those 
with a delusional BDD or depression [15, 45].  
The trial included participants of a representative population of BDD (for 
example both sexes, varied ages, symptoms of features that are common in BDD and 
participants with or without medication and who are likely to present in a psychiatric 
setting). Given the wide variety of demographic characteristics and recruitment from 
standard routes of referral, it is reasonable to assume that the intervention can 
potentially generalise to other settings if a therapist can build experience in treating 
BDD. When considering CBT for BDD, slight caution is required in future meta-
analyses as not all forms of CBT for BDD are identical. For example, meta-cognitive 
therapy [18] evaluated in a recent trial, or CBT for BDD as published by Wilhelm et 
al., (2013)[46] overlaps with our protocol, but is based on somewhat different 
conceptualisation and interventions.  
We do not have sufficient information on the mechanism of change in either 
group. The AAI was measured weekly to identify the frequency of the cognitive 
processes and safety seeking behaviours that are conceptualised to be important in 
maintaining preoccupation, distress and handicap related to a distorted bo
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BDD. During CBT these processes decreased steadily, and more than they did in AM 
and were associated with reductions in symptoms of BDD. A much larger study 
would be required to demonstrate that such processes may mediate change. The 
optimum length of treatment would appear to be at least 16 sessions. The trajectory of 
the outcome scores beyond 16 weeks suggests that some patients may benefit from 
more than 20 sessions especially if one includes modules for depression or other 
comorbidity [47]. Future protocols of CBT might also include loading the frequency 
of sessions at the beginning of therapy (for example twice weekly for the first 4 
weeks). This would be similar to the original cognitive therapy protocol for treating 
depression [48], the rationale being to maximize engagement and also improve 
symptoms of depression.   
Limitations 
 The study has a relatively small sample that may over-estimate effect size. 
Although there were no significant differences for the CEQ and other measures 
between the groups at baseline, the small sample size may have led to a Type II error. 
The analysis of the sub-sample for depression and delusional BDD may also be 
subject to a Type II error. Small sample size may also have led to the difficulty in 
identifying any predictors of outcome. Trials of clinical effectiveness with larger 
sample sizes are therefore required. No formal testing of blindness of the rater was 
conducted and our group could be accused of having an investigator bias towards 
CBT. However we believed that requesting the research assessor to guess blinding 
would be biased as it may be influenced by her rating of the outcome. The study is 
also limited by not reporting reliability data on the directiveness and therapeutic 
relationship scales, which may have been biased by measurement error. The study 
may have benefitted from a standard quality of life measure alongside the main 
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outcomes and reporting on the inter-rater reliability of the adherence ratings. 
Delivering 12 sessions of therapy may have resulted in less gains being achieved at 
our primary outcome. A 12 week duration may have been too brief to achieve 
significant changes BDD and depression. An optimal therapy length may well be 
between 16 and 24 sessions. However, the aim of this particular study was to 
demonstrate the specific nature of the CBT in comparison to AM. 
The design of the study compared unequal lengths of treatments as the CBT 
group received 16 weeks of sessions whereas the AM group received only 12. 
However the outcome measures were only compared between the groups at 12 weeks. 
Within-group effects were only analysed for CBT from 12 to16 weeks. It would have 
been beneficial to do the same for AM so that implications of the findings could go 
beyond 12 weeks for both interventions, however it was deemed unethical to continue 
AM for longer than 12 weeks (discussed above). Currently we are unable to conclude 
higher effectiveness of CBT in comparison to AM post 12 weeks of intervention. In 
addition, follow-up outcomes analysed for both AM and CBT groups were only 
conducted at 1 month post-treatment. It may have been optimal to consider the 
maintenance of study outcomes over a longer-term follow-up period. The research 
was conducted at a single centre with specialist expertise in BDD and further research 
is required to determine the generalizability of the findings in other settings. 
Further research  
The study suggests that gains are maintained at 1-month follow-up for the 
CBT group. Further research is required to compare treatments at the same end-point 
beyond 12 weeks and to determine long-term follow-up of one year or more, in order 
to better consider efficacy of treatments.  CBT is a complex intervention and there is a 
need to unbundle specific modules such as imagery rescripting to determine their 
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effectiveness and contribution to the package. Although about half our participants 
were already stabilised on a SSRI at enrolment, many were not taking a maximum 
dose. Future controlled trials are required to determine whether the outcome of CBT 
is enhanced by augmentation of SSRIs at the maximum tolerated dose. Although it is 
gratifying that there was a large effect size by 16 weeks and 52% had a significant 
clinical response, nearly half remain non-responders. It may be that a longer or more 
intensive CBT or in a residential setting will be more beneficial to some participants. 
This is not surprising given the chronicity of their problems, previous failure of 
treatment and the frequent comorbidity. Further research is required to develop CBT 
for this difficult to treat population. Lastly it would be helpful to determine the cost-
effectiveness of CBT, whether CBT can be successful in adolescents, how long it 
should optimally be delivered for in different groups and whether it can be adapted to 
different settings especially in dermatology and cosmetic surgery clinics, where a 
cognitive behaviour therapist could be sited alongside the physician or surgeon.   
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Table 1. Characteristics of participants and by group 
 Total  
 
 
n = 46 
Cognitive 
Behaviour 
Therapy  
n = 21 
Anxiety 
Management  
Training 
n = 25 
Statistic  
Age in years, Median &   
Interquartile Range (IQR)  
30.0 (25.0-36.5) 30.0 (24.5-37.5) 29.0 (25.5-
37.0) 
U = 256,  
Z = -.14,  
p = .87 
Sex, n (%)  
   Male 
   Female 
 
19 (41.3) 
27 (58.7) 
 
  9 (42.9) 
12 (57.1) 
 
10 (40.0) 
15 (60.0) 
 
Fisher’s Exact Test p = 1 
Marital Status, n (%)  
   Single  
   Married  
   Separated or Divorced 
 
30 (65.2) 
12 (26.1) 
  3 (  6.5) 
 
13 (61.9) 
  8 (38.1) 
  0 ( 0.0) 
 
17 (68.0) 
  5 (20.0) 
  3 (12.0) 
 
Fisher’s Exact Test p = .35 
Ethnicity, n (%)  
White 
Black 
Mixed black and white 
South Asian 
 
37 (80.4) 
  5 (10.9) 
  2 (  4.3) 
  2 (  4.3) 
 
16 (76.2) 
  2 (  9.5) 
  2 (  9.5) 
  1 (  4.8) 
 
21 (84.0) 
  3 (12.0) 
  1 ( 4.0) 
  0 ( 0.0) 
 
Fisher’s Exact Test p = .62 
Employment, n (%)  
Unemployed 
Long-term sick leave 
Employed or self-employed 
Retired 
Student (full time) 
Homemaker 
 
14 (30.4) 
  2 (  4.3) 
21 (45.7) 
  1 (  2.2) 
  5 (10.9) 
  3 (  6.5) 
 
  3 (14.3) 
  1 (  4.8) 
12 (57.1) 
  0 (0) 
  3 (14.3) 
  2 (  9.5) 
 
11 (44.0) 
  1 (  4.0) 
  9 (36.0) 
  1 (  4.0) 
  2 (  8.0) 
  1 (  4.0) 
 
Fisher’s Exact Test p = .22 
Referral 
Local Primary care 
   Secondary care 
  
 
37 (80.4) 
  9 (19.6) 
  
 
 17 (81.0) 
   4 (19.0) 
   
 
20 (80) 
   5 (20) 
   
 
Fisher’s Exact Test p = 1 
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Duration of problem in years,  
Median (IQR)     
 
 
11.0 (6.75-16.5) 
 
14.0 (8.0-23.0) 
 
10.0 (6.0-15.5) 
U = 206,  
Z = -1.25,  
p = .21 
Current Comorbidity, n (%) 
Delusional BDD  
Depression  
Social Phobia 
Obsessive Compulsive Disorder  
28 (60.9) 
25 (54.3) 
20 (43.5) 
  5 (10.9) 
  2 (  4.3) 
12 (57.1) 
11 (52.4) 
  9 (42.9) 
  1 (  4.8) 
  1 (  4.8) 
16 (64.0) 
14 (56.0) 
11 (44.0) 
  4 (16.0) 
  1 (  4.0) 
 
Fisher’s Exact Test p =.69 
MADRS score at baseline, n (%) 
Moderate depression >25 
Severe depression >31 
 
12 (26.1) 
21 (45.7) 
 
5 (23.8) 
9 (42.9) 
 
7 (28.0) 
12 (57.1) 
 
Fisher’s Exact Test p = .80 
Current SSRI, n (%)  
Median prescribed daily SSRI dosage (mg) 
(IQR) 
21 (45.7)  
60 (20.0-60.0) 
 
 12 (57.1) 
 40 (32.5-55.0) 
 
  9 (36.0) 
20 (20.0-60.0) 
U = 36.5,  
Z = -1.3,  
p = .22 
Previous CBT for BDD, n (%) 
   Yes  
No 
 
17 (37.0) 
29 (63.0) 
 
8 (38.1) 
  13 (61.9) 
 
  9 (36.0) 
16 (64.0) 
 
Fisher’s Exact Test p = 1 
Previous SSRI, n (%) 
Yes  
No  
 
22 (61.1) 
14 (38.9) 
 
11 (64.7) 
  6 (35.3) 
 
11 (57.9) 
  8 (42.1) 
 
Fisher’s Exact Test p = .74 
Desire at least 1 cosmetic procedure n  (%) 
Yes 
No 
 
36 (83.7) 
  7 (16.3) 
 
17 (81.0) 
  4 (19.0) 
 
19 (86.4) 
  3 (13.6) 
 
Fisher’s Exact Test p = .70 
At least 1 past cosmetic procedure n (%) 
Yes 
No 
 
15 (33.3) 
30 (66.7) 
 
 4 (19.0) 
17 (81.0) 
 
11 (45.8) 
13 (54.2) 
 
Fisher’s Exact Test p = .07 
Credibility Expectancy Questionnaire 
Credibility, Median (IQR) 
(Range 3-27)  
Expectancy, Median (IQR)  
(Range 3-27) 
 
5.7 (3.33-7) 
 
3.2 (2.03-7.12) 
   
6.0 (3.17-7.67) 
 
 6.0 (1.62-7.71) 
 
 
5.2 (3.33-6.50) 
 
3.0 (2.26-4.35) 
U = 89.5, 
Z = -0.7, 
p  = .94 
U = 79.0, 
Z = -0.6, 
p  = .58 
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Figure 1. CONSORT flow diagram of participants 
 
 
 
 
Assessed for eligibility 
( ) 
Excluded  (n= 40) ♦   Not meeting inclusion criteria 
(n= 31) ♦   Time constraints attending or 
did not attend again (n=8) ♦   Lack of funding (n=1) ♦   Had previous CBT  in past 6 
 
Analysed  (n= 21) ♦ Excluded from analysis (n= 0)  
Followed up at 1 months (n= 17)                
Lost to follow-up (n=0)  
Allocated to CBT (n= 21) ♦ Received CBT for 12 weeks (n= 19) ♦ Did not receive full CBT (1 drop out 
at week 9 and 1 at week 12) (n= 2) 
Further 4 weeks of wait list (n = 20) 
Discontinued wait list (n= 1)  
Allocated to Anxiety Management (n= 
25) ♦ Received AMT for 12 weeks (n= 20) ♦ Did not receive full AMT (1 drop out 
at week 1  3  5  9 and 12 (n=5) 
Analysed  (n= 25) ♦ Excluded from analysis (n= 0)  
 
Allocation 
Analysis 
Follow-Up 
Randomized (n= 46) 
Enrollment 
Further 4 sessions of CBT (n= 19) ♦ Received CBT (n= 17) ♦ Did not receive further CBT (1 drop 
out at week 13 and 1 at week 14) 
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Table 2 Linear growth models for change in outcomes over time. (C.I Confidence Interval)  
 Baseline – W12 
  
Growth 
 
Parameter Estimates 
 Parameter β Standard 
Error β p C.I. 
Dependent 
Variable 
 
     
BDD-
YBOCS 
Treatment 4.99 3.24 .124 -1.36, 11.34 
 Time 
-4.81 1.84  < .01 -8.43, -1.20 
 Treatment*Time 
-7.19 2.61 < .01 -12.31, -2.07 
MADRS Treatment 1.33 5.02 .791 -8.51, 11.16 
 Time 
-4.06 2.15 .059 -8.28, .155 
 Treatment*Time 
-2.80 3.12 .370 -8.91, 3.32 
BABS Treatment 3.72 2.76 .178 -1.69, 9.14 
 Time 
-1.04 1.42 .467 -3.83, 1.76 
 Treatment*Time 
-4.45 2.11 . < .05 -8.58, -.315 
AAI Treatment 6.98 4.06 .085 -.972, 14.94 
 Time 
-4.41 2.09 . < .05 -8.53, -.287 
 Treatment*Time 
-7.87 2.87 . < .01 -13.50, -2.24 
PHQ-9 Treatment 3.14 3.64 .389 -4.00, 10.28 
 Time 
-.327 1.75 .852 -3.77, 3.11 
 Treatment*Time 
-3.64 2.53 .149 -8.60, 1.31 
35 
 
GAD-7 Treatment 1.08 3.28 .742 -5.36, 7.52 
 Time 
-1.50 1.53 .330. -4.51, 1.52 
 Treatment*Time 
-2.83 2.13 .185 -7.02, 1.36 
BIQLI Treatment 
-1.20 .564 < .05 -2.31, -.098 
 Time 
-.368 .240 .125  -.838, .103 
 Treatment*Time 
.908 .350 < .01 .223, 1.59 
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Table 3 Comparisons of group outcomes.  
Within-group Between-group 
  
Cognitive Behavioural Therapy n = 21 
 
 
Anxiety Management Training n = 25 
 
CBT vs AM 
Measure Baseline 
M (SD) 
Week 
12       
M (SD) 
Week 
16        
M (SD) 
1mFU 
M (SD) 
Statistics  
Baseline-W12 
Statistics 
Baseline-W16 
Statistics 
Baseline-1mFU 
Baseline    
M (SD) 
Week 12        
M (SD) 
1mFU        
M (SD) 
Statistics 
Baseline-W12 
Statistics 
Baseline-1mFU 
Week 12 
Cohen’s d 
BDD-
YBOCS 
35.48 
(6.61) 
23.47 
(11.23) 
20.87 
(10.5) 
 
21.37 
(12.42) 
t (20) = 5.18  
p < .001  
d = 1.30 
t (20) = 5.70  
p < .001  
d = 1.67 
t (20) = 5.35    
 p < .001 
d = 1.42 
37.68 
(4.77) 
32.87 
(7.45) 
33.30 
(8.72) 
t (24) = 3.19   
p < .01  
d = 0.77 
t (24) = 2.32        
p < .05 
d =0.62 
0.99 
MADRS 28.57 
(10.69) 
21.71 
(11.20) 
17.64 
(12.38) 
20.40 
(13.14) 
t (20) = 3.13,  
p < .01 
d = 0.63 
t (20) = 3.75,  
p < .001 
d = 0.95 
t (20) = 2.53     
p < .05  
d = 0.68 
30.04 
(9.62) 
25.98 
(10.80) 
28.63 
(13.32) 
t (24) = 1.87   
p > .05 
d = 0.40 
t (24) = .55          
p > .05  
d = 0.12 
0.39 
BABS 18.24 
(4.68) 
12.75  
(8.11) 
10.90  
(7.07) 
10.28 
(7.41) 
t (20) = 3.12  
p < .01 
d = 0.83 
t (20) = 3.87  
p < .001 
d = 1.22 
t (20) = 4.58 
p <.001 
d = 1.28 
18.96 
(4.14) 
17.92 
(5.42) 
18.88 
(4.62) 
t (24) = .86 
p > .05  
d = 0.22 
t (24) = .097        
p > .05  
d = 0.02 
0.75 
AAI 26.89 
(6.62) 
14.61  
(9.20) 
13.70 
(10.51) 
14.16 
(9.53) 
t (20) = 6.98 
p < .001  
d = 1.53 
t (20) = 6.06 
p < .001 
d = 1.50 
t (20) = 5.13 
p <.001 
d = 1.55 
27.78 
(7.03) 
23.37 
(8.29) 
23.21 
(8.86) 
t (24) = 1.99 
p < .05  
d = 0.57 
t (24) = 1.95        
p > .05 
d = 0.57 
1.00 
PHQ-9 13.1 
(6.50) 
9.12    
(7.01) 
8.88  
(7.24) 
9.41   
(6.67) 
t (20) = .100 
p < .05  
d = 0.59 
t (20) = 2.40 
p < .05  
d = 0.61 
t (20) = 1.82 
p > .05  
 d = -0.56 
13.60 
(5.44) 
13.28 
(7.18) 
15.79 
(7.05) 
t (24) = .190       
p > .05  
d = 0.05 
t (24) = -1.45        
p > .05  
\d = -0.35 
0.59 
GAD-7 11.33 
(6.32) 
7.00    
(6.02) 
7.23  
(6.24) 
8.53 
(6.60) 
t (20) = 2.70 
p < .01  
d = 0.70 
t (20) = 2.31  
p < .05   
d = 0.65 
t (20) = 1.68,      
p > .05 
d = 0.43 
13.09 
(5.24) 
11.59 
(5.89) 
13.22 
(5.45) 
t (24) = 1.04   
p > .05  
d = 0.27 
t (24) = -.107        
p > .05  
d = -0.02 
0.77 
BIQLI -1.97 
(0.56) 
 
-1.43   
(0.85) 
-1.30   
(0.90) 
-1.29 
(0.92) 
t (20) = -.560 
p < .05  
d = -0.75 
t (20) = -2.89  
p < .01 
d = -0.89 
t (20) = -2.38,      
p < .05  
d = .-0.89 
-1.68 
(1.04) 
-2.04 
(0.71) 
-1.95 
(0.81) 
t (24) = 1.37 
p > .05  
d = 0.40 
t (24) = .920        
p > .05  
d = 0.29 
0.78 
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